Among patients with inflammatory bowel disease older than 60 years, thiopurines were associated with an increased risk for non-infectious and non-neoplastic adverse events, according to study results.
Míriam Mañosa, of the IBD Unit at Hospital Universitari Germans Trias i Pujol in Spain, and colleagues wrote that starting immunosuppressant therapy in older patients with IBD can be difficult because of the associated comorbidities and polypharmacy.
“Physiological changes in the elderly patients may impact the pharmacokinetics of orally administered drugs,” they wrote in

Source link